Phase II trial of panitumumab with irinotecan as salvage therapy for patients with advanced or recurrent colorectal cancer (TOPIC study)
Irinotecan dose escalation according to the UGT1A1 genotype | Download Table
Irinotecan – Wikipedia
All You Need to Know About UGT1A1 Genetic Testing for Patients Treated With Irinotecan: A Practitioner-Friendly Guide | JCO Oncology Practice
First-Line Liposomal Irinotecan–Containing Regimen Studied in Advanced Pancreatic Cancer - The ASCO Post
Frontiers | Microbiota-Host-Irinotecan Axis: A New Insight Toward Irinotecan Chemotherapy
Pre-therapeutic UGT1A1 genotyping to reduce the risk of irinotecan-induced severe toxicity: Ready for prime time - European Journal of Cancer
359 Erhöhte Irinotecan-Toxizität bei reduzierter UGT1A1-Aktivität - IMD Institut für medizinische Diagnostik, Labor
Irinotecan hydrochloride (Onivyde) - wikidoc
NDC 72485-213-15 Irinotecan Hydrochloride Injection Intravenous
Irinotecan Hydrochloride, USP - Xiromed
irinotecan
Selective TACE with irinotecan-loaded 40 μm microspheres and FOLFIRI for colorectal liver metastases: phase I dose escalation pharmacokinetic study | BMC Cancer | Full Text
Irinotecan Intravenous: Uses, Side Effects, Interactions, Pictures, Warnings & Dosing - WebMD
Irinotecan Hydrochloride Injection, SDV | Eugia US
Modified XELIRI (capecitabine plus irinotecan) versus FOLFIRI (leucovorin, fluorouracil, and irinotecan), both either with or without bevacizumab, as second-line therapy for metastatic colorectal cancer (AXEPT): a multicentre, open-label, randomised ...
Liposomal irinotecan (Onivyde): Exemplifying the benefits of nanotherapeutic drugs - Milano - 2022 - Cancer Science - Wiley Online Library
DBL Irinotecan Full Prescribing Information, Dosage & Side Effects | MIMS Malaysia
Irinotecan Actavis
Irinotecan Pathway, Pharmacokinetics
Phase I study of cisplatin, irinotecan, and epirubicin administered every 3 weeks in patients with advanced solid tumours | British Journal of Cancer
Dose Escalation and DLT of Increased Irinotecan Doses in Patients... | Download Table
UGT1A1*28 genotype and irinotecan dosage in patients with metastatic colorectal cancer: a Dutch Colorectal Cancer Group study | British Journal of Cancer
![Pharmacokinetics, Metabolism, and Excretion of Irinotecan (CPT-11) Following I.V. Infusion of [14C]CPT-11 in Cancer Patients | Drug Metabolism & Disposition](https://dmd.aspetjournals.org/content/dmd/28/4/423/F1.large.jpg "Pharmacokinetics, Metabolism, and Excretion of Irinotecan (CPT-11) Following I.V. Infusion of [14C]CPT-11 in Cancer Patients | Drug Metabolism & Disposition")
Pharmacokinetics, Metabolism, and Excretion of Irinotecan (CPT-11) Following I.V. Infusion of [14C]CPT-11 in Cancer Patients | Drug Metabolism & Disposition
